Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 26Gynecologic 12Gastrointestinal 12Tumor-Agnostic 7Genitourinary 7Other solid neoplasm 6CNS 3Breast 3Sarcoma 2Other hematologic neoplasm 2Head & Neck 2NET 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 1Carcinoid Tumor 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
nintedanib × Endocrine × Clear all
NCT02399215 2023-12-26

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 2 Completed
32 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡